Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2009
02/12/2009WO2009018824A1 Use of a composition comprising at least one beta-blocker for the treatment of sleep disorders
02/12/2009WO2009018811A1 Novel pharmaceuticals, method for the production thereof, and use thereof in medical therapy
02/12/2009WO2009018807A1 Oxazolidinones as factor xa inhibitors, methods for the production thereof, and use thereof in therapy
02/12/2009WO2009018780A1 Andrographolide derivatives and use thereof in manufacture of medicaments
02/12/2009WO2009018748A1 Use of 2,5-dihydroxyphenymethanol or its derivates in preparing the medicine or functional food for treating or preventing depression
02/12/2009WO2009018747A1 The application of 3, 5-dihydroxytoluene or derivatives thereof in the preparation of medicine and functional for treating or preventing depression.
02/12/2009WO2009018726A1 An antrodia camphorata cyclohexenone compound used for inhibiting hepatitis b virus
02/12/2009WO2009018723A1 Sulfonyl-substituted carbapenem compounds
02/12/2009WO2009018662A1 Renin inhibitors
02/12/2009WO2009018657A1 Viral polymerase inhibitors
02/12/2009WO2009018656A1 Viral polymerase inhibitors
02/12/2009WO2009018622A1 Lactation-associated polypeptides
02/12/2009WO2009018609A1 Hepatitis c antiviral compositions and methods
02/12/2009WO2009009739A3 Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer
02/12/2009WO2009002652A9 Use of surfactants for treating mycobacterial infections
02/12/2009WO2009002529A3 Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
02/12/2009WO2009000954A3 Use of estriol in low doses
02/12/2009WO2009000909A8 Salts of perindopril
02/12/2009WO2008157840A3 Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
02/12/2009WO2008157208A3 Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
02/12/2009WO2008157003A3 Chemical inhibitors of bfl-1 and related methods
02/12/2009WO2008156868A3 Compositions and methods of treating chronic kidney disease
02/12/2009WO2008156614A3 Imidazopyrazines as protein kinase inhibitors
02/12/2009WO2008155594A3 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof
02/12/2009WO2008155421A3 Indolin-2-ones and aza-indolin-2-ones
02/12/2009WO2008154466A3 Control of ectoparasites
02/12/2009WO2008153945A3 Nutraceutical co-crystal compositions
02/12/2009WO2008152260A3 Novel rar receptor agonist ligands and use thereof in human medicine and cosmetics
02/12/2009WO2008152073A3 Piperazine compounds with a herbicidal action
02/12/2009WO2008146284A3 Crystalline rotigotine base and preparation process therefor
02/12/2009WO2008144061A3 Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
02/12/2009WO2008142231A3 Novel composition based on cholest-4-ene-3-one oxime
02/12/2009WO2008137753A3 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
02/12/2009WO2008135527A3 Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
02/12/2009WO2008133734A4 Method and compositions for treating hiv infections
02/12/2009WO2008131807A3 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
02/12/2009WO2008128028A3 Solifenacin compositions
02/12/2009WO2008127349A3 Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
02/12/2009WO2008127287A3 Materials and methods for wound treatment
02/12/2009WO2008126932A3 Epigenetical regulation of brain plasticity
02/12/2009WO2008121817A3 Quinoline derivatives and pharmaceutical compositions comprising them for selectin inhibition
02/12/2009WO2008116129A3 Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
02/12/2009WO2008109495A3 Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof
02/12/2009WO2008109454A4 Nucleic acid compounds for inhibiting fos gene expression and uses thereof
02/12/2009WO2008107480A8 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators
02/12/2009WO2008105822A8 Antimicrobial compositions
02/12/2009WO2008104386A3 Method for the treatment of amyloidoses
02/12/2009WO2008098985A3 Pharmaceutical composition for the treatment of il-8 mediated diseases
02/12/2009WO2008092928A3 NOVEL ß-LACTAM ANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF
02/12/2009WO2008089426A3 Methods and compositions for the delivery of a therapeutic agent
02/12/2009WO2008087643A3 Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
02/12/2009WO2008086330A3 Formulations of deacetylase inhibitors
02/12/2009WO2008079355A3 Method and system for enhancing self-treatment of onychomycosis
02/12/2009WO2008076780A3 Amorphous valsartan and the production thereof
02/12/2009WO2008073865A3 Method of preventing or treating myocardial ischemia
02/12/2009WO2008073661A3 Long term disease modification using immunostimulatory oligonucleotides
02/12/2009WO2008071605A3 Methods of treating inflammatory diseases
02/12/2009WO2008068584A3 A heterogeneously configured multiparticulate gastrointestinal drug delivery system
02/12/2009WO2008057933A3 Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
02/12/2009WO2008045663A3 Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
02/12/2009WO2008038292A3 Use of glycerophospholipids for joint lubrication
02/12/2009WO2008036067A3 Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
02/12/2009WO2008034120A3 Lysine-based polymeric linkers
02/12/2009WO2008033460A3 Treating pain, diabetes, and lipid metabolism disorders
02/12/2009WO2008028963A3 Calreticulin for its use as a medication for the treatment of cancer in a mammal
02/12/2009WO2008012089A8 Polyphenol/peptide composition and use thereof for promoting gastric health
02/12/2009WO2008011599A3 Phosphorylated glucomannan polysaccharide for receptor mediated activation and maturation of monocyte-derived dendritic cells
02/12/2009WO2008008539A3 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
02/12/2009WO2008008024A3 Polymorphic forms of spirapril hydrochloride
02/12/2009WO2008004058A3 Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
02/12/2009WO2007146335A3 Compounds and compositions for treatment of cancer
02/12/2009WO2007139827A8 Optimized fluorocarbon emulsions for blood substitutes and other therapeutic uses
02/12/2009WO2007134169A3 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
02/12/2009WO2007096882A3 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
02/12/2009WO2007091037A3 Metal-containing virucidal compositions and uses
02/12/2009US20090044299 Artichoke hybrid named 'PS-H2015'
02/12/2009US20090043399 Use of fucans for the purpose of bone grafting, engineering and regeneration
02/12/2009US20090043388 Drug eluting coatings for medical implants
02/12/2009US20090043379 Drug delivery systems for the prevention and treatment of vascular diseases
02/12/2009US20090043378 Biocompatible Polymer System for Extended Drug Release
02/12/2009US20090043129 Potent and selective ligands of cannabinoid receptors
02/12/2009US20090042996 reduced fluorine content increases cost efficiency
02/12/2009US20090042995 Therapeutic formulation
02/12/2009US20090042993 Identification of novel post-translational protein modifications
02/12/2009US20090042992 Polymorphs of suberoylanilide hydroxamic acid
02/12/2009US20090042991 Methods of increasing natural killer cell activity for therapy
02/12/2009US20090042990 adding benzoic acid to increase bone resistance and mineralization
02/12/2009US20090042989 Nsaid formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
02/12/2009US20090042988 Pharmaceutical compositions containing a meglitinide compound for preventing hepatic fibrosis
02/12/2009US20090042987 Treatment of neuropathic pain
02/12/2009US20090042985 Process for the Preparation of Fatty Acids
02/12/2009US20090042984 Cool-Pet System
02/12/2009US20090042983 Use of L-carnitine for the treatment of cardiovascular diseases
02/12/2009US20090042982 Method for treating neurological disorders using acetone derivatives
02/12/2009US20090042981 FDA Orange book listed patent for fesoterodine fumarate; urinary incontinence; isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester is fesoteridine
02/12/2009US20090042980 Neuroprotective compositions and methods
02/12/2009US20090042979 Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
02/12/2009US20090042978 Pharmaceutical Compositions Containing Nitrovinylfuran Derivatives for the Treatment of Leishmaniosis and Trypanosomosis
02/12/2009US20090042977 Anticancer Compound, Intermediate Therefor, and Processes for Producing These
02/12/2009US20090042976 Antimicrobial therapy for bacterial infections